Latest Conference Articles

March 31st 2017, 2:30am

ACCC Annual Meeting, CANCERSCAPE

Cary Presant, MD, FACP, FASCO, City of Hope Medical Center, discusses clinical trials and value-based care.

March 30th 2017, 10:49pm

ACCC Annual Meeting, CANCERSCAPE

The Republican-led Affordable Care Act repeal and replace effort has the potential to be revived, but majority leaders may not want to risk further political capital in a battle that could go against them, speakers said at this year's Association of Community Cancer Centers' CANCERSCAPE annual conference.

March 19th 2017, 2:34am

St. Gallen International Breast Cancer Conference

Wolfgang Janni, MD, PhD, University of Ulm, disucusses the management of adverse events in HER2-targeted therapies.

March 19th 2017, 2:30am

St. Gallen International Breast Cancer Conference

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

March 19th 2017, 12:03am

St. Gallen International Breast Cancer Conference

Neoadjuvant therapy in early breast cancer has evolved during the past 2 decades from use primarily in large inoperable tumors to a standard treatment option for patients with early-stage HER2-positive and triple-negative breast cancer.

March 18th 2017, 10:37pm

St. Gallen International Breast Cancer Conference

Age and the molecular subtype were more closely associated with long-term outcomes compared with the use of either breast-conserving surgery or mastectomy for patients with breast cancer.

March 18th 2017, 9:46pm

St. Gallen International Breast Cancer Conference

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.

March 17th 2017, 11:30pm

St. Gallen International Breast Cancer Conference

The paucity of patients participating in clinical trials makes data extrapolation and application complex, calling for a need to explore health technology solutions that tap the potential of real-world data.

March 17th 2017, 10:23pm

St. Gallen International Breast Cancer Conference

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor-positive/HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

March 17th 2017, 8:41pm

State of the Science Summit on GI Malignancies

Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.

March 17th 2017, 7:01pm

St. Gallen International Breast Cancer Conference

Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.

March 17th 2017, 6:15pm

St. Gallen International Breast Cancer Conference

Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

March 17th 2017, 6:05pm

State of the Science Summit on GI Malignancies

Brian Hemphill, MD, provides insight on some of the challenges currently being faced in gastrointestinal malignancies and how molecular profiles of tumors will dramatically change outcomes for these patients.

March 17th 2017, 5:49pm

St. Gallen International Breast Cancer Conference

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses the importance of de-escalating treatment in early-stage breast cancer.

March 17th 2017, 1:12am

St. Gallen International Breast Cancer Conference

Genomic studies have made significant advancements in discovering methods to combat resistance to endocrine therapy in patients with hormone receptor (HR)–positive breast cancer over the past few years, according to Ian E. Krop, MD, PhD. Of particular interest are combination therapies blocking multiple driver pathways and resistance mechanisms.

March 17th 2017, 12:57am

St. Gallen International Breast Cancer Conference

Updated findings from the MONALEESA-2 trial demonstrated that the response to ribociclib (Kisqali) in postmenopausal women with hormone-receptor-positive/HER2-negative advanced or metastatic breast cancer was unaffected by either prior endocrine treatment or prior chemotherapy.

March 16th 2017, 10:38pm

State of the Science Summit on GI Malignancies

Bert O'Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.

March 16th 2017, 9:17pm

St. Gallen International Breast Cancer Conference

C. Kent Osborne, MD, discusses current strategies for overcoming resistance to HER2-targeting agents in early breast cancer today.

March 16th 2017, 6:30pm

State of the Science Summit on GI Malignancies

Johanna Bendell, MD, discusses the promising impact of immunotherapy and other emerging agents in the field of gastrointestinal cancer.

March 16th 2017, 5:41pm

St. Gallen International Breast Cancer Conference

Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.